Zacks: Leap Therapeutics Inc (LPTX) Given $15.50 Consensus Target Price by Analysts

Shares of Leap Therapeutics Inc (NASDAQ:LPTX) have earned a consensus broker rating score of 1.50 (Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company.

Analysts have set a 12 month consensus price target of $15.50 for the company and are anticipating that the company will post ($0.77) EPS for the current quarter, according to Zacks. Zacks has also assigned Leap Therapeutics an industry rank of 193 out of 265 based on the ratings given to related companies.

Separately, Zacks Investment Research cut Leap Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, January 19th.

In related news, COO Augustine Lawlor purchased 1,057,769 shares of the stock in a transaction on Tuesday, November 14th. The shares were purchased at an average cost of $6.09 per share, for a total transaction of $6,441,813.21. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 58.40% of the company’s stock.

Leap Therapeutics (LPTX) traded up $0.18 on Tuesday, hitting $6.24. The stock had a trading volume of 97,952 shares, compared to its average volume of 68,874. Leap Therapeutics has a 1-year low of $4.90 and a 1-year high of $9.44.

Leap Therapeutics (NASDAQ:LPTX) last released its quarterly earnings data on Monday, November 13th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.11). analysts predict that Leap Therapeutics will post -3.63 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Zacks: Leap Therapeutics Inc (LPTX) Given $15.50 Consensus Target Price by Analysts” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://ledgergazette.com/2018/02/11/zacks-leap-therapeutics-inc-lptx-given-15-50-consensus-target-price-by-analysts.html.

About Leap Therapeutics

Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).

Get a free copy of the Zacks research report on Leap Therapeutics (LPTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply